Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | Exciting results from CARTITUDE-1: anti-BCMA CAR-T for MM

Jesús Berdeja • 7 Dec 2019
ASH 2019
Multiple Myeloma CAR-T Ciltacabtagene autoleucel
CARTITUDE-1

Ciltacabtagene autoleucel (cilta-cel; formerly JNJ-4528) is CAR T-cell therapy containing two BCMA-targeting single-domain antibodies designed to confer avidity. Jesus Berdeja, MD, Director of Myeloma Research, Sarah Cannon Research Institute, Nashville, TN, discusses the results from the CARTITUDE-1 trial (NCT03548207), a Phase Ib/II study of cilta-cel in patients with relapsed and/or refractory multiple myeloma (MM). Dr Berdeja highlights the very exciting results, including measurable residual disease (MRD) negativity in all evaluable patients tested and a manageable safety profile. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Jesús Berdeja

1:22
Multiple myeloma highlights at ASH 2020
Jesús Berdeja • 11 Dec 2020
2:38
CRB-402 study update: T-cell phenotypes in myeloma
Jesús Berdeja • 11 Dec 2020
1:55
Impact of age on ide-cel efficacy in the KarMMa trial
Jesús Berdeja • 11 Dec 2020
4:10
Update on CARTITUDE-1: CAR-T in RRMM
Jesús Berdeja • 26 May 2020

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals